ERBB2 and gastroesophageal junction adenocarcinoma: Patients with locally advanced or metastatic HER2‐positive gastric cancer or gastroesophageal junction adenocarcinoma, who had previously undergone trastuzumab‐based therapy, were granted US FDA approval to receive T‐DXd on January 15, 2021.124